Skip to main content

Table 1 Studies and patients characteristics

From: Indications and outcomes of enterovesical and colovesical fistulas: systematic review of the literature and meta-analysis of prevalence

Author

Year of publication

Years of enrollment

Quality of evidence (OCEBM)

Country

No. of surgically treated patients

Mean age

Male:female

Etiology

Type of fistula

 

Pollard

1987

1971–1986

4

UK

61

61

36:25

DD 71%; CRC 12.1%; BC 1.5%; CD 6%; PR 4.5%; Appendicitis 3%; Trauma 1.5%

CVF 100%

 

McNamara

1990

1952–1986

2b

Canada

61

34.4

38:23

CD 100%

EVF 85.2%; RVF 4.9%; CVF 9.8%

 

Holmes

1992

1988–1991

4

UK

11

69

8:3

CRC 63.6%; BC 36.4%

CVF 100%

 

McBeath

1994

1980–1991

2b

USA

76

62.1

51:25

DD 59%; Malignancy 9%; PR 7%; Radioneoplastic 8%; CD 9%;

Appendicitis 3%; other 6%

  

Munoz

1998

1980–1995

4

USA

33

62

56:6

Benign disease 27%; Malignancy 73%

  

Vasilevsky

1998

1975–1995

4

Canada

23

 

8:15

DD 100%

CVF 100%

 

Yamamoto

2000

1970–1997

4

Japan

25

39

17:8

CD 100%

EVF 80%; CVF 20%

 

Walker

2002

1991–1995

2b

UK

19

68

8:11

DD 73.6%; CRC 15.7%; Trauma 5.2%; CD 5.2%

CVF 100%

 

Menenakos

2003

1993–2002

2b

Greece

15

68.1

10:5

DD 100%

CVF 100%

 

Najjar

2004

1992–2004

4

USA

12

63.9

12:0

DD 75%; CRC 16.7%; BC 8.3%

CVF 100%

 

Kavanagh

2005

1990–2000

4

Ireland

25

63.5

13:12

DD 52%; CRC 16%; BC 4%; CD 12%; PR 12%; IA 4%

CVF 76.7%; RVF 13.3%; EVF 10%

 

Laurent

2005

1992–2003

4

Belgium

16

60

10:6

DD 100%

CVF 100%

 

Ferguson

2008

1993–2005

4

USA

74

54

48:26

DD 70.3%; CD 29.7%

  

Melchior

2009

1982–2007

4

Germany

49

69.5

42:7

DD 100%

CVF 100%

 

Lynn

2012

2003–2010

2b

USA

72

60

50:22

DD 65%; Malignancy 15%; CD 18%; Trauma 2%

CVF 85%; RVF 15%

 

Niebling

2013

1998–2010

4

Netherlands

31

61.1

19:12

DD 100%

CVF 100%

 

Maciel

2014

2009–2013

2b

USA

75

62.3

39:36

DD 100%

CVF 100%

 

Salgado-Nesme

2016

2005–2011

2b

Mexico

24

56.5

22:2

DD 100%

CVF 100%

 

Taxonera

2016

NR

2b

Spain

79

33

60:19

CD 100%

EVF 66.9%; CVF 31.9%

 

Badic

2017

2000–2014

2b

France

28

68

20:8

DD 100%

CVF 100%

 

El-Haddad

2018

2012–2017

4

Egypt

40

58

36:4

DD 100%

CVF 100%

 

Nevo

2019

2007–2017

4

Israel

17

48 (median)

15:2

DD 59%; CD 41%

EVF 41%; CVF 59%

 
  1. OCEBM Oxford Center of Evidence Based Medicine, CVF colovesical fistula, RVF rectovesical fistula, EVF enterovesical fistula, DD Diverticular disease, CD Crohn disease, CRC colo-rectal cancer, BC bladder cancer, PC prostate cancer, PR post radiation, IA iatrogenic